All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback